Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Stomach Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Esophageal Neoplasms 3Sarcoma 2Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Solid Cancer 1Sarcoma, Synovial 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Metastatic Gastric Adenocarcinoma 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Liver Neoplasms 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Renal Cell 1Carcinoma 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Cyclophosphamide 3Imatinib Mesylate 2temsirolimus 1tazemetostat 1sapanisertib 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1aldesleukin 1Zoledronic Acid 1Sunitinib 1Ramucirumab 1Nivolumab 1Methotrexate 1Leukapheresis 1Interleukin-2 1Injections 1Immunotherapy, Adoptive 1Ifosfamide 1HhAntag691 1Gemcitabine 1Everolimus 1Epirubicin 1Doxorubicin 1Docetaxel 1Decitabine 1Dacarbazine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma, Synovial × Ramucirumab × Clear all
NCT04145700 2023-09-13

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Eli Lilly and Company

Phase 1/2 Terminated
23 enrolled 15 charts
Sarcoma

Sarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡